Dual Targeting of Syndecan-1 and Glucose Transporter-1 With a Novel Lipid-Based Delivery System Enhances Therapeutic Efficacy and Overcomes Chemoresistance in Pancreatic Ductal Adenocarcinoma

Gastroenterology. 2025 Jan;168(1):160-163.e4. doi: 10.1053/j.gastro.2024.09.009. Epub 2024 Sep 14.
No abstract available